| Document Date: 2008-12-11 13:03:24
Open Document File Size: 76,32 KBShare Result on Facebook
City New York / Parsippany / Mountain View / / Company Pergamon Press / Novartis Consumer Health Inc. / ALZA Corporation / / Country United States / / Event Product Recall / Product Issues / / Facility Laboratory Test Interactions Scopolamine / Hospital Pharmacists / / IndustryTerm Glaucoma therapy / overdosage involving multiple patch applications / patch site / aluminized transdermal systems / dangerous machinery / mineral oil / / MedicalCondition glaucoma / acute narrow-angle glaucoma / urinary bladder neck obstruction / post-operative nausea / headache / CNS depression / urinary retention / seizures / coma / hallucinations / convulsion / nausea / both disorders / muscle weakness / motion sickness / drowsiness / bradycardia / tachycardia / restlessness / vomiting center / hypotension / motion-induced nausea / intestinal obstruction / Skin burns / hypertension / Carcinogenesis / WARNINGS Glaucoma / disorientation / Sickness / erythema / lethargy / vomiting / pain / Dizziness / abdominal cramps / tachyarrhythmias / occasionally observed syndrome / / MedicalTreatment surgery / / MusicGroup Nausea / / Organization American Society of Hospital Pharmacists / / Person Transderm Scop / / Position physician / PRECAUTIONS General / head / behind the ear / / Product Drug / Transderm Scop / liver / / ProvinceOrState New Jersey / New York / California / / PublishedMedium Magnetic Resonance Imaging / / Technology MRI / Pharmacokinetics / Magnetic Resonance Imaging / /
SocialTag |
¯ Transderm Scop scopolamine 1.5 mg Transdermal Therapeutic System Programmed to deliver in-vivo approximately